投稿问答最小化  关闭

2022年纯生信SCI数量已接近1500篇,前两名期刊来自同一出版社,肿瘤类占比85%

2022/7/12 16:30:41  阅读:3347 发布者:

2022年已经过了一半,上个月底SCI影响因子已更新,10分以上期刊已经超过600本,在年终总结之前,我们回顾一下生信SCI见刊趋势还乐观吗?肿瘤类的还好发生信文章吗?哪些期刊对生信分析友好?非肿瘤的生信好发文章吗?

跟着小编一起看个究竟。

为了获取Pubmed中纯生信类SCI的清单,我们进行了关键词检索Gene expression Omnibus”“TCGA,然后获取的清单进行并集处理:

2022年纯生信友好期刊排行榜出炉,1-6月纯生信文章高达1344篇,亮点如下:

1)  30本杂志,占到总接收数量的50%

2)  15本生信友好期刊的影响因子高于5分。

3)  4本杂志中,有3本来自于Frontiers出版社,发文量这么大,明年影响因子会不会下跌呢?

4)高分杂志Clin Cancer ResNature communicationsCell Death Dis等,每个月只接收1篇生信类SCI

如果按照期刊的接收数量排序的话,如下:

 

2022纯生信友好期刊

2022接收量

影响

因子

Front Genet

76

4.772

Front Oncol

72

5.738

Int J Gen Med

36

2.145

Front Immunol

33

8.786

BMC Cancer

33

4.638

Dis Markers

31

3.464

Ann Transl Med

26

3.616

Front Cell Dev Biol(预警)

24

6.081

Comput Math Methods Med

24

2.809

Sci Rep(预警)

23

4.379

J Oncol

23

4.501

Cancers (Basel)

18

6.575

Biomed Res Int

17

3.246

Aging (Albany NY)

17

5.955

Gene

16

3.913

Cancer Cell Int

16

6.429

Front Cardiovasc 

Med

14

5.846

Genes (Basel)

13

4.141

PLoS One(预警)

12

3.752

Int J Mol Sci

12

5.924

Comb Chem High Throughput Screen

11

1.714

Oxid Med Cell 

Longev

11

7.31 

J Clin Lab Anal

11

3.124

Front Mol Biosci

11

6.113

Bioengineered

11

6.832

PeerJ

10

3.061

J Transl Med

10

8.44

J Exp Clin Cancer 

Res

10

12.658

J Cancer

10

4.478

Front Endocrinol 

(Lausanne)

10

6.055

Cell Death Dis

10

9.685

 

如果按照影响因子IF大小排序,如下:

 

2022纯生信友好期刊

影响因子

2022接收量

J Exp Clin Cancer 

Res

12.658

10

Cell Death Dis

9.685

10

Front Immunol

8.786

33

J Transl Med

8.44

10

Oxid Med Cell 

Longev

7.31

11

Bioengineered

6.832

11

Cancers (Basel)

6.575

18

Cancer Cell Int

6.429

16

Front Mol Biosci

6.113

11

Front Cell Dev Biol(预警)

6.081

24

Front Endocrinol (Lausanne)

6.055

10

Aging (Albany NY)

5.955

17

Int J Mol Sci

5.924

12

Front Cardiovasc 

Med

5.846

14

Front Oncol

5.738

72

Front Genet

4.772

76

BMC Cancer

4.638

33

J Oncol

4.501

23

J Cancer

4.478

10

Sci Rep(预警)

4.379

23

Genes (Basel)

4.141

13

Gene

3.913

16

PLoS One(预警)

3.752

12

Ann Transl Med

3.616

26

Dis Markers

3.464

31

Biomed Res Int

3.246

17

J Clin Lab Anal

3.124

11

PeerJ

3.061

10

Comput Math Methods Med

2.809

24

Int J Gen Med

2.145

36

Comb Chem High Throughput Screen

1.714

12

 

我们主要了解一下3-8分之间的生信SCI,如何才能短平快地发。

首先是5-8的,列举一些案例(大部分是免疫相关分析):

Binding blockade between TLN1 and integrin β1 represses triple-negative breast cancer

Elife

8.713

Global and context-specific transcriptional consequences of oncogenic Fbw7 mutations

Elife

8.713

A loss-of-function polymorphism in ATG16L1 compromises therapeutic outcome in head and neck carcinoma patients

Oncoimmunology

7.723

Deep learning using bulk RNA-seq data expands cell landscape identification in tumor microenvironment

Oncoimmunology

7.723

Comprehensive Analysis of CDK1-Associated ceRNA Network Revealing the Key Pathways LINC00460/LINC00525-Hsa-Mir-338-FAM111/ZWINT as Prognostic Biomarkers in Lung Adenocarcinoma Combined with Experiments

Cells

7.666

A Novel Attention-Mechanism Based Cox Survival Model by Exploiting Pan-Cancer Empirical Genomic Information

Cells

7.666

The clinical relevance of epithelial-mesenchymal transition and its correlations with tumorigenic immune infiltrates in hepatocellular carcinoma

Immunology

7.215

 

4-5分级别的投这几个:

 

Gene Interaction Network Analysis Reveals IFI44L as a Drug Target in Rheumatoid Arthritis and Periodontitis

Molecules

4.927

Discovering Common miRNA Signatures Underlying Female-Specific Cancers via a Machine Learning Approach Driven by the Cancer Hallmark ERBB

Biomedicines

4.757

Butyrate Inhibits Colorectal Cancer Cell Proliferation through Autophagy Degradation of β-Catenin Regardless of APC and β-Catenin Mutational Status

Biomedicines

4.757

Integrative analysis of cell adhesion molecules in glioblastoma identified prostaglandin F2 receptor inhibitor (PTGFRN) as an essential gene

BMC

Cancer

4.638

PIK3R3, a regulatory subunit of PI3K, modulates ovarian cancer stem cells and ovarian cancer development and progression by integrative analysis

BMC

Cancer

4.638

Cystatin SN promotes epithelial-mesenchymal transition and serves as a prognostic biomarker in lung adenocarcinoma

BMC

Cancer

4.638

The feasibility of proteomics sequencing based immune-related prognostic signature for predicting clinical outcomes of bladder cancer patients

BMC

Cancer

4.638

Identification of a pyroptosis-related prognostic signature in breast cancer

BMC

Cancer

4.638

A new finding in the key prognosis-related proto-oncogene FYN in hepatocellular carcinoma based on the WGCNA hub-gene screening trategy

BMC

Cancer

4.638

Survival-related indicators ALOX12B and SPRR1A are associated with DNA damage repair and tumor microenvironment status in HPV 16-negative head and neck squamous cell carcinoma patients

BMC

Cancer

4.638

 

3-4级别的投这几个:

 

A hierarchical spike-and-slab model for pan-cancer survival using pan-omic data

BMC Bioinformatics

3.307

Comparison of five supervised feature selection algorithms leading to top features and gene signatures from multi-omics data in cancer

BMC Bioinformatics

3.307

Overlapping group screening for detection of gene-environment interactions with application to TCGA high-dimensional survival genomic data

BMC Bioinformatics

3.307

Identification of miRNA biomarkers for stomach adenocarcinoma

BMC Bioinformatics

3.307

Machine-learning algorithms based on personalized pathways for a novel predictive model for the diagnosis of hepatocellular carcinoma

BMC Bioinformatics

3.307

Diagnostic and prognostic values of pyroptosis-related genes for the hepatocellular carcinoma

BMC Bioinformatics

3.307

Feature screening for survival trait with application to TCGA high-dimensional genomic data

PeerJ

3.061

Identification of potential biomarkers of vascular calcification using bioinformatics analysis and validation in vivo

PeerJ

3.061

Identification of key differential genes in intimal hyperplasia induced by left carotid artery ligation

PeerJ

3.061

转自: 学术查

如有侵权,请联系本站删除!


  • 万维QQ投稿交流群    招募志愿者

    版权所有 Copyright@2009-2015豫ICP证合字09037080号

     纯自助论文投稿平台    E-mail:eshukan@163.com